Commentary to "chromogranin a: biological function and clinical utility in neuroendocrine tumor disease".
作者信息
Jeske Wojciech, Glinicki Piotr, Kapuścińska Renata
出版信息
Ann Surg Oncol. 2011 Jan;18(1):293. doi: 10.1245/s10434-010-1146-5. Epub 2010 Jun 12.
Abstract
摘要
相似文献
1
Commentary to "chromogranin a: biological function and clinical utility in neuroendocrine tumor disease".
Ann Surg Oncol. 2011 Jan;18(1):293. doi: 10.1245/s10434-010-1146-5. Epub 2010 Jun 12.
2
Analytical evaluation of a second generation assay for chromogranin A; a dual-site study.
Clin Chem Lab Med. 2016 Apr;54(4):e139-42. doi: 10.1515/cclm-2015-0782.
3
Quantifying the effects of renal impairment on plasma concentrations of the neuroendocrine neoplasia biomarkers chromogranin A, chromogranin B, and cocaine- and amphetamine-regulated transcript.
Clin Chem. 2012 May;58(5):941-3. doi: 10.1373/clinchem.2011.176099. Epub 2012 Feb 23.
4
Chromogranin As a Biochemical Marker of Neuroendocrine Tumors.
Bull Exp Biol Med. 2016 Mar;160(5):702-4. doi: 10.1007/s10517-016-3254-0. Epub 2016 Mar 29.
5
Chromogranin A--biological function and clinical utility in neuro endocrine tumor disease.
Ann Surg Oncol. 2010 Sep;17(9):2427-43. doi: 10.1245/s10434-010-1006-3. Epub 2010 Mar 9.
6
Re: Biological variation of neuroendocrine tumor markers chromogranin A and neuron-specific enolase.
Clin Biochem. 2013 Aug;46(12):1145. doi: 10.1016/j.clinbiochem.2013.04.010. Epub 2013 Apr 19.
7
Comparison of the utility of Cocaine- and Amphetamine-Regulated Transcript (CART), chromogranin A, and chromogranin B in neuroendocrine tumor diagnosis and assessment of disease progression.
J Clin Endocrinol Metab. 2015 Apr;100(4):1520-8. doi: 10.1210/jc.2014-3640. Epub 2015 Feb 9.
8
Diagnostic value of chromogranin A in pancreatic neuroendocrine tumors depends on tumor size: A prospective observational study from a single institute.
Surgery. 2017 Jul;162(1):120-130. doi: 10.1016/j.surg.2017.01.019. Epub 2017 Mar 2.
9
[Chromogranin A (CgA) - characteristic of the currently available laboratory methods and conditions which can influence the results].
Endokrynol Pol. 2009 Sep-Oct;60(5):415-9.
10
Blood Chromogranin A Is Not Effective as a Biomarker for Diagnosis or Management of Bronchopulmonary Neuroendocrine Tumors/Neoplasms.
Neuroendocrinology. 2020;110(3-4):185-197. doi: 10.1159/000500202. Epub 2019 Apr 16.
本文引用的文献
1
The differences in chromogranin A (CgA) concentrations measured in serum and in plasma by IRMA and ELISA methods.
Endokrynol Pol. 2010 Jul-Aug;61(4):346-50.
2
Chromogranin A--biological function and clinical utility in neuro endocrine tumor disease.
Ann Surg Oncol. 2010 Sep;17(9):2427-43. doi: 10.1245/s10434-010-1006-3. Epub 2010 Mar 9.
3
Validation of serum versus plasma measurements of chromogranin a levels in patients with carcinoid tumors: lack of correlation between absolute chromogranin a levels and symptom frequency.
Pancreas. 2006 Oct;33(3):250-4. doi: 10.1097/01.mpa.0000235302.73615.d4.
Zotero 插件